Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes.
BACKGROUND
Candidate genes of psychological importance include 5HT2A, 5HT2C, and COMT, implicated in the serotonin, noradrenaline and dopamine pathways, which also may be involved in regulation of energy balance. We investigated the associations of single nucleotide polymorphisms (SNPs) of these genes with obesity and metabolic traits.


RESULTS
In a population of 166 200 young men examined at the draft boards, obese men (n = 726, BMI> or =31.0 kg/m(2)) and a randomly selected group (n = 831) were re-examined at two surveys at mean ages 46 and 49 years (S-46, S-49). Anthropometric, physiological and biochemical measures were available. Logistic regression analyses were used to assess age-adjusted odds ratios. No significant associations were observed of 5HT2A rs6311, 5HT2C rs3813929 and COMT rs4680 with obesity, except that COMT rs4680 GG-genotype was associated with fat-BMI (OR = 1.08, CI = 1.01-1.16). The SNPs were associated with a number of physiological variables; most importantly 5HT2C rs3813929 T-allele was associated with glucose (OR = 4.56, CI = 1.13-18.4) and acute insulin response (OR = 0.65, CI = 0.44-0.94) in S-49. COMT rs4680 GG-genotype was associated with glucose (OR = 1.04, CI = 1.00-1.09). Except for an association between 5HT2A rs6311 and total-cholesterol at both surveys, significant in S-46 (OR = 2.66, CI = 1.11-6.40), no significant associations were observed for the other phenotypes. Significant associations were obtained when combined genotype of 5HT2C rs3813929 and COMT rs4680 were examined in relation to BMI (OR = 1.12, CI = 1.03-1.21), fat-BMI (OR = 1.22, CI = 1.08-1.38), waist (OR = 1.13, CI = 1.04-1.22), and cholesterol (OR = 5.60, CI = 0.99-31.4). Analyses of impaired glucose tolerance (IGT) and type 2 diabetes (T2D) revealed, a 12.3% increased frequency of 5HT2C rs3813929 T-allele and an 11.6% increased frequency of COMT rs4680 GG-genotype in individuals with IGT or T2D (chi(2), p = 0.05 and p = 0.06, respectively). Examination of the combined genotypes of 5HT2C and COMT showed a 34.0% increased frequency of IGT or T2D (chi(2), p = 0.01).


CONCLUSIONS
The findings lend further support to the involvement of serotonin, noradrenaline and dopamine pathways on obesity and glucose homeostasis, in particular when combined genotype associations are explored.
Kring
Sofia I I
SI
Institute of Preventive Medicine, Copenhagen University Hospital, Centre for Health and Society, Copenhagen, Denmark. SI@ipm.regionh.dk
Werge
Thomas
T
Holst
Claus
C
Toubro
Søren
S
Astrup
Arne
A
Hansen
Torben
T
Pedersen
Oluf
O
Sørensen
Thorkild I A
TI
D002394:Catechol O-Methyltransferase / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics*; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics*; D044405:Receptor, Serotonin, 5-HT2C / Q000235:genetics*
D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D002394:Catechol O-Methyltransferase
Curr Drug Targets. 2005 Mar;6(2):201-13
15777190
Lancet. 2002 Jun 15;359(9323):2086-7
12086765
Ann Hum Genet. 1999 Jul;63(Pt 4):329-40
10738544
BMC Genet. 2007 Oct 16;8:70
17937824
Ann Hum Genet. 2006 May;70(Pt 3):293-303
16674552
J Psychiatr Res. 2003 May-Jun;37(3):193-220
12650740
Int Rev Psychiatry. 2007 Oct;19(5):523-30
17896232
Hum Genet. 2007 Aug;122(1):41-9
17497175
Pharmacol Rev. 1999 Dec;51(4):593-628
10581325
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1021-8
15953671
Lancet. 2007 Jan 6;369(9555):71-7
17208644
BMJ. 1989 Sep 23;299(6702):767-70
2508915
Psychopharmacology (Berl). 2003 Apr;167(1):72-8
12632246
Ann N Y Acad Sci. 2002 Jun;967:571-5
12079891
Pharmacogenet Genomics. 2008 Feb;18(2):153-9
18192901
Int J Obes (Lond). 2005 Jun;29(6):624-31
15824752
Anesthesiology. 2008 Jul;109(1):137-48
18580184
J Neurosci. 2004 Jun 9;24(23):5331-5
15190105
Science. 2005 Jan 21;307(5708):375-9
15662002
Curr Drug Targets. 2004 Apr;5(3):221-40
15058309
Metabolism. 2008 May;57(5):708-11
18442637
Diabet Med. 2005 Sep;22(9):1199-205
16108849
World Health Organ Tech Rep Ser. 1995;854:1-452
8594834
Am J Physiol. 1990 Oct;259(4 Pt 2):R829-35
2221150
Diabetologia. 2007 Sep;50(9):1880-1888
17624514
Lancet. 2001 Feb 3;357(9253):354-7
11210998
Genet Res. 2005 Dec;86(3):223-31
16454861
Nature. 2000 Apr 6;404(6778):661-71
10766253
Obes Res. 2002 Jul;10(7):585-9
12105278
Obes Facts. 2008;1(3):138-45
20054173
N Engl J Med. 2005 Nov 17;353(20):2121-34
16291982
Med Hypotheses. 2004;62(6):976-9
15142660
Ann Hum Genet. 2006 Mar;70(Pt 2):262-76
16626336
Brain Res Mol Brain Res. 2004 Aug 23;127(1-2):39-47
15306119
Eur J Pharmacol. 2008 May 6;585(1):38-49
18407262
Am J Epidemiol. 1996 Aug 1;144(3):207-13
8686689
Am J Med Genet B Neuropsychiatr Genet. 2004 Apr 1;126B(1):124-7
15048662
Mol Psychiatry. 2007 Aug;12(8):707-47
17549063
Neuroimage. 2008 Apr 15;40(3):1175-80
18291676
Ann Med. 2001 Nov;33(8):534-41
11730160
Obesity (Silver Spring). 2008 Jun;16(6):1363-9
18356831
Biometrics. 1976 Sep;32(3):599-606
963173
Diabetologia. 2003 Jan;46(1):3-19
12637977
Am J Psychiatry. 2003 Jan;160(1):90-9
12505806
Diabetes Care. 2007 Feb;30(2):257-62
17259491
Diabetologia. 2000 Mar;43(3):373-6
10768099